A detailed history of Sphera Funds Management Ltd. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 1,191,140 shares of INZY stock, worth $3.2 Million. This represents 1.14% of its overall portfolio holdings.

Number of Shares
1,191,140
Previous 1,462,724 18.57%
Holding current value
$3.2 Million
Previous $6.52 Million 4.51%
% of portfolio
1.14%
Previous 0.95%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.31 - $6.0 $1.17 Million - $1.63 Million
-271,584 Reduced 18.57%
1,191,140 $6.23 Million
Q2 2024

Aug 14, 2024

BUY
$4.33 - $7.31 $388,907 - $656,562
89,817 Added 6.54%
1,462,724 $6.52 Million
Q1 2024

May 15, 2024

SELL
$4.14 - $7.66 $786,599 - $1.46 Million
-190,000 Reduced 12.16%
1,372,907 $10.5 Million
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $888,880 - $1.48 Million
328,000 Added 26.56%
1,562,907 $6.66 Million
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $421,024 - $720,580
102,940 Added 9.09%
1,234,907 $5.19 Million
Q2 2023

Aug 14, 2023

SELL
$4.93 - $6.74 $3.2 Million - $4.38 Million
-649,891 Reduced 36.47%
1,131,967 $6.31 Million
Q1 2023

May 15, 2023

BUY
$1.3 - $5.73 $203,840 - $898,464
156,800 Added 9.65%
1,781,858 $10.2 Million
Q4 2022

Feb 14, 2023

BUY
$1.05 - $2.82 $472,500 - $1.27 Million
450,000 Added 38.3%
1,625,058 $1.71 Million
Q3 2022

Nov 14, 2022

BUY
$2.57 - $5.45 $24,307 - $51,546
9,458 Added 0.81%
1,175,058 $3.15 Million
Q2 2022

Aug 15, 2022

BUY
$3.2 - $5.96 $3.73 Million - $6.95 Million
1,165,600 New
1,165,600 $5.56 Million
Q4 2020

Feb 16, 2021

SELL
$19.95 - $27.55 $3.92 Million - $5.41 Million
-196,411 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$17.54 - $30.2 $3.45 Million - $5.93 Million
196,411 New
196,411 $5.16 Million

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $108M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.